This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
- ALA:
- α-linolenic acid
- ARA:
- arachidonic acid
- DHA:
- docosahexaenoic acid
- EFAD:
- essential fatty acid deficiency
- EPA:
- eicosapentaenoic acid
- FDA:
- Food and Drug Administration
- FXR:
- farnesoid X receptor
- IFALD:
- intestinal failure–associated liver disease
- ILE:
- intravenous lipid emulsion
- LA:
- linoleic acid
- LXR:
- liver X receptor
- MCT:
- medium-chain triglyceride
- PN:
- parenteral nutrition
- PUFA:
- polyunsaturated fatty acid
- SO:
- soybean oil
Abstract
The clinical goals of intravenous lipid emulsions (ILEs) have changed since their initial development. In the past, 100% soybean oil was used to provide energy and prevent an essential fatty acid deficiency. Now, different oil sources are used with the goal of improving nutritional status and preventing common neonatal comorbidities. We now have a better understanding of specific ILE constituents, namely, fatty acids, vitamin E, and phytosterols, and how these components contribute to complications such as intestinal failure–associated liver disease. This review addresses the development and composition of different ILEs and summarizes how individual ILE ingredients affect infant metabolism and health.
- Copyright © 2020 by the American Academy of Pediatrics
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
